

Contents

	<i>page</i>
Certificate	<i>i</i>
Declaration	<i>ii</i>
Acknowledgements	<i>iii-v</i>
Abstract	<i>vi-vii</i>
List of Publications	<i>viii-ix</i>
Contents	<i>x-xiv</i>
List of Figures	<i>xiv-xx</i>
List of Tables	<i>xx</i>
List of Symbols	<i>xx</i>
List of Abbreviations	<i>xxi-xxii</i>

Chapter 1: Introduction

1.1 Duchenne Muscular Dystrophy: A Rare Genetic Disorder.	1-2
1.2 Role of Dystrophin Protein	2
1.3 DIAGNOSIS OF DMD	3
1.4 DISEASE PROGRESSION OF DMD	3
1.4.1 Pathogenesis of DMD	4-6
1.5 DIFFERENT TYPES OF MUTATION IN DMD GENE	6-7
1.6 Therapeutic strategies for DMD	7-9
1.6.1 THERAPEUTIC APPROACHES IN CLINICAL STAGE OF DEVELOPMENT	9
1.6.1.1 Dystrophin restoration therapies via anti-sense mediated exon skipping strategy	9-10
1.6.1.2 Antisense oligonucleotides (ASOs)	10-11
1.6.1.3 Cell Penetrating Peptides (CPPs)	11-14
1.6.1.4 CPP Conjugated ASOs	14-15
1.6.1.5 Utrophin Modulation	15-16
1.7 Research Objectives	16
1.8 Thesis Overlay	17
1.9 Research Contribution	18
1.10 Discussion and Future Prospect	18-19
1.11 References	19-25

Chapter 2: Quinazoline and Quinoline-Based Small Molecules as Utrophin Upregulators for Duchenne Muscular Dystrophy

2.1 Abstract	26
2.2 Introduction	26-28
2.3 Results and Discussion	
2.3.1 Design of Utrophin Modulators Based on Quinoline and Quinazoline scaffold	28-29
2.3.2 In-silico Molecular Docking Analysis	30-31
2.3.3 Chemistry	31-40
2.3.4. Screening of Molecular Library by High-throughput In-Cell ELISA Technique	41-43
2.3.5 Cellular Cytotoxicity	43-44
2.3.6 Structure Activity Relationship	44-49
2.3.7 qRT-PCR and Western Blot of Hit Molecules Identified	49-50
2.3.8 Utrophin Protein Expression in Human Patient Derived DMD Cell Line	50-51
2.3.9 Target Validation for Lead Molecule SG-02	51-52
2.3.10 Fusion Assay	52-54
2.3.11 In-Vitro ADME Study	
2.3.11.1 Aqueous Solubility Assay	54
2.3.11.2 Microsomal Stability Assay	54-55
2.3.11.3 Serum Stability Assay	55
2.3.11.4 Lipophilicity Assay	56
2.4 Experimental Section	
2.4.1. Materials	56-57
2.4.2 Methods	
2.4.2.1 Synthesis of molecular library	57-59
2.4.2.2 Cell Viability	59-60
2.4.2.3 Screening of Molecular Library by High-throughput In-Cell ELISA Technique	60
2.4.2.4 RNA Extraction and Reverse Transcription-Polymerase Chain Reaction	56
2.4.2.5 Protein Isolation and Western Blot Analysis	60-61
2.4.2.6 Fluorescence Quenching Assay of SG-02 with AhR: ARNT	61
2.4.2.7 Immunofluorescence Analysis of AhR Localization	61-62
2.4.2.8 Myoblast Fusion	62
2.4.2.9 MyHC RNA Extraction and Reverse Transcription-Polymerase Chain Reaction	62
2.4.2.10 Protein Isolation from Patient Derived Human Cell Line (KM1328) and Dot Blot Analysis	63

2.4.2.11 Microsomal Stability Assay	63
2.4.2.12 Aqueous Solubility Assay	63
2.4.2.13 Serum Stability Assay	64
2.4.2.14 Lipophilicity assay	64
2.4.2.15 Molecular Docking Studies	64
2.5 Conclusion	65
2.6 References	65-68
Chapter 3: Delivery of Antisense Oligonucleotide through Chemical Conjugation with Designed Short Non-Cationic Cell Penetrating Peptide using Click Chemistry for Duchenne Muscular Dystrophy	
3.1 Abstract	69
3.2 Introduction	69-71
3.3 Results and Discussion	
3.3.1 Design and Synthesis of Cell penetrating peptides	71-73
3.3.2 Conjugation of azide functionalized CPPs with alkyne containing ASO and vice versa	73-76
3.3.3 Conjugation of N-terminal azide functionalized CPPs with active alkyne containing ASO	76-94
3.3.4 Monitoring of click chemistry reaction via Infrared Spectroscopy	95
3.3.5 Mechanistic Pathway associated with uptake of Cell Penetrating Peptide ETWWK	95
3.3.6 Cytotoxicity of the designed Cell penetrating peptides	96-97
3.3.7 Cellular uptake study by immunocytochemistry and flow cytometry	97-99
3.3.8 qRT-PCR of ETWWK-ASO construct	99
3.4. Materials and Methods	
3.4.1 Materials	100
3.4.2 Methods	
3.4.2.1 Synthesis of Cell Penetrating Peptides	101
3.4.2.2 Synthesis of Azo transfer reagent, Imidazole-1-sulfonyl Azide Hydrogen Sulfate	101
3.4.2.3 Solid phase N-terminal amine to azide transfer by utilizing Imidazole-1-sulfonyl Azide. H ₂ SO ₄	101-102
3.4.2.4 Synthesis of an alkyne linker for conjugation to ASO	102
3.4.2.5 Conjugation of synthesized alkyne linker to free amino linker of ASO	102-103
3.4.2.6 Conjugation of CPPs with ASO via Click Chemistry in solid support	
3.4.2.6.1 Conjugation of N-terminal Azide containing CPPs with Alkyne functionalized ASO under ligand free condition	103-104
3.4.2.6.2 Conjugation of N-terminal Azide containing CPPs with Alkyne functionalized ASO in presence of TBTA and (BimH) ₃	104

3.4.2.7. Synthesis of 5-carboxy fluorescein conjugated Cell Penetrating Peptide (ETWWK-FAM)	104-105
3.4.2.8 Conjugation of ETWWK-FAM with ASO	105
3.4.2.9. ESI-MS analysis for the peptide conjugated ASO	105
3.4.2.10 Cytotoxicity Assay	105
3.4.2.11. Cellular imaging and uptake assay	
3.4.2.11.1 Immunocytochemistry	106
3.4.2.11.2 Flow Cytometry Studies	106-107
3.4.2.12 Dystrophin RNA Extraction and Reverse Transcription-Polymerase Chain Reaction	107
3.4.2.13 Serum stability assay for synthesized cell penetrating peptides	107-108
3.5 Conclusion	108-109
3.6 References	110-114

Chapter 4: Mitochondrial Targeted Engineered Peptide Based Therapeutics for Managing Duchenne Muscular Dystrophy Pathophysiology via Enhancing Myogenesis and Mitigating Fibrosis

4.1 Abstract	115
4.2 Introduction	115-117
4.3 Results and Discussion	
4.3.1 Design and synthesis of mitochondria targeted peptides	117-118
4.3.2 Screening of Peptide Library by High-throughput In-Cell ELISA Technique	118-119
4.3.3 Mechanistic pathway behind cellular internalization and mitochondrial localization	119-121
4.3.4 Fusion Assay	121-122
4.3.5 Protein and mRNA expression of E.M.P-2	122-124
4.3.6 Maintaining Calcium homeostasis by E.M.P-2	124-126
4.3.7 Downregulation of pro-inflammatory marker IL-6, and fibrosis marker COL1A1 by E.M.P-2	126-127
4.3.8 Cytotoxicity and serum stability of the lead engineered peptide E.M.P-2	126-128
4.4 Materials and Methods	
4.4.1 Materials	128-129
4.4.2 Methods	
4.4.2.1 Synthesis of Peptide Library	129
4.4.2.2 Synthesis of TPP conjugated lead peptide E.M.P-2	130
4.4.2.3 Synthesis of 5-carboxy fluorescein conjugated TPP-E.M.P-2	130-132
4.4.2.4 UV-Vis fluorescence spectroscopy	132
4.4.2.5 Fluorescence spectroscopy	132
4.4.2.6 CD Spectroscopy	132
4.4.2.7 Zeta Potential	133

4.4.2.8 Cytotoxicity Study	133
4.4.2.9 Serum stability assay for lead engineered peptide E.M.P-2	133
4.4.2.10 Flow Cytometry Studies	133-134
4.4.2.11 In Cell ELISA	134
4.4.2.12 RNA extraction and quantitative reverse transcriptase- PCR (RT-qPCR)	134-135
4.4.2.13 Dot Blot for protein expression	135
4.4.2.14 Mitotracker	135
4.4.2.15 Immunocytochemistry	135
4.5 Conclusion	136-137
4.6 References	137-141
Chapter 5: Summary and Future Perspective	
5.1 Summary	142-146
5.2 FUTURE PERSPECTIVE	146-148
APPENDIX A	149-193
APPENDIX B	194-202

List of Figures

Figures	Title	Page
1.1	Comparative illustration of an intact muscle membrane (top panel) in which dystrophin anchors the dystrophin-glycoprotein complex (DGC) to the actin cytoskeleton, versus a dystrophin-deficient membrane (bottom panel) showing membrane instability associated with DMD. Comparison depicts differences between a healthy muscle cell in a normal boy and a dystrophic muscle cell in a boy with DMD. Image reproduced from Houang <i>et al.</i> , Skeletal Muscle, 2018 with copyright permission).	1
1.2	Illustrative representation of the progression of DMD disease starting from deposition of fat and scar tissue to dysfunction of heart muscle.	4
1.3	Different mutations in DMD gene. A) Mutation spectrum of DMD gene in the cohort. B) Deletion mutations in the DMD gene exhibits two hotspot regions: Proximal (exons 1–22) and distal (exons 43–55)	7
1.4	Chemical structures of PMO and 2'OMe-PS subunits	10
1.5	Schematic representation of the cellular uptake mechanisms for CPPs or CPP-Cargo complexes. Two main pathways of internalization are illustrated: direct translocation and endocytosis. Image reproduced from Cell-Penetrating Peptides - Creative Peptides Blog.	14
1.6	Replacement of utrophin with dystrophin during early human development, from 10 to 25 weeks of fetal development	16